Among the most important changes in the regulation of the Russian pharmaceutical industry in the 1st quarter of 2023, the following can be distinguished:
Roman Shabrov, partner at BRACE commented for Pharmaceutical Bulletin magazine on the case of an anti-competitive agreement on the Chlorhexedine antiseptic market, identified by the FAS Russia, the resolution of which was appealed by the companies held liable.
In July 2021, the Eurasian Economic Commission issued an update that from July 1, 2021, medicinal products should be registered according to the unified rules of the EAEU. These rules were approved by the Decision of the Council of the Economic Commission dated 03.01.2017 No. 78 “On the rules for registration and examination of medicines for medical use”. At the same...
Recall that earlier by Appendix No. 5 to the Rules of Compulsory Medical Insurance, approved by order of the Ministry of Health of the Russian Federation No. 108n dated February 28, 2019, determining the coefficients of the amount of non-payment or incomplete payment of the costs of a medical organization for the provision of medical care as a basis for...
By the Decree of the Government of the Russian Federation of June 30, 2021 No. 1069 “On Amendments to the Regulation on the Monitoring System for the Movement of Medicinal Products”, this period was determined until February 1, 2022. Thus, the simplified procedure for working in the medicinal product labeling and tracking system in Russia is prolonged for another 7...